Drug intelligence / Profile preview

Reprograbetes

Development stage: Unknown
Lead developer: Qurgen
Modality: Recombinant Proteins and Enzymes

Overview

Reprograbetes is a protein-based regenerative medicine candidate developed by Qurgen for the treatment of diabetes. Currently in Phase 2 clinical development, the therapeutic is designed to induce the in vivo reprogramming of pancreatic cells into functional, insulin-producing beta cells. By leveraging a proprietary protein delivery platform, Reprograbetes aims to restore endogenous glycemic control, potentially providing a disease-modifying or curative solution that reduces or eliminates the need for chronic exogenous insulin administration in patients with diabetes.

Beyond the preview

Go deeper on Reprograbetes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reprograbetes.

Explore the full profile